Daan Gene Co., Ltd. (SZSE: 002030)
Health Care · Biotechnology · CN
CN¥5.60
-2.95% today · -21.3% 1Y
Daan Gene Co., Ltd. (SZSE: 002030) operates in the Biotechnology industry within the Health Care sector. The company is valued at $1.17B and employs 1,506 people.
Over the last twelve months the share price has lost 21.3%, trading between 4.80 and 8.20.
Tweenvest scores Daan Gene Co., Ltd. across four factors: quality 65/100, value 47/100, growth 17/100. Its strongest factor is quality.
002030 price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $1.17B
- Revenue (TTM)
- $106.99M
- P/E
- —
- EPS
- -0.63
- Dividend yield
- —
- Beta (5Y)
- 0.45
- 52-week high
- CN¥8.20
- 52-week low
- CN¥4.80
- Avg volume (3M)
- —
- Shares outstanding
- 1.40B
- Employees
- 1,506
- Next earnings
- —
About Daan Gene Co., Ltd.
Daan Gene Co., Ltd. specializes in the research, development, manufacturing, and commercialization of clinical diagnostic reagents and instruments. The company's extensive product portfolio encompasses advanced solutions such as fluorescence quantitative PCR products, time-resolved series diagnostics, enzyme-linked immunoassay (EIA) kits, various diagnostic instruments, and specialized scientific research services. Beyond product offerings, the company extends its expertise to provide comprehensive medical examination and health management services. These encompass a wide range of offerings, from genetic susceptibility gene testing and tumor marker analysis to crucial cervical cancer screening and general routine physical examinations, alongside other personalized health support. Established in 2001, the company was originally known as Da An Gene Co., Ltd. of Sun Yat-Sen University. It is presently headquartered in Guangzhou, located in the People's Republic of China.
- ISIN
- CNE000001KP1
- Founded
- 1988
- Listed since
- Aug 9, 2004
- Exchange
- Shenzhen Stock Exchange
- Currency
- CNY
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $468.22B | $265.43 | +0.18% |
| Amgen Inc.NasdaqGS: AMGN | $237.52B | $440.98 | +0.38% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $181.18B | $146.44 | +0.22% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.91B | $548.78 | +0.13% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.28B | $825.89 | -0.98% |
| argenx SEENXTBR: ARGX | $65.85B | €864.20 | -4.19% |
| Moderna, Inc.NasdaqGS: MRNA | $57.92B | $139.44 | -3.88% |
| CSL LimitedASX: CSL | $57.77B | AU$168.30 | -1.69% |
Figures last refreshed Aug 18, 2026.